UK markets closed

Verona Pharma plc (VRNA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
7.34+0.06 (+0.82%)
At close: 4:00PM EDT
7.47 +0.13 (1.77%)
After hours: 05:42PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close7.28
Bid7.47 x 1200
Ask7.70 x 900
Day's range7.21 - 7.46
52-week range4.40 - 15.71
Avg. volume72,593
Market cap425.487M
Beta (5Y monthly)0.51
PE ratio (TTM)N/A
EPS (TTM)-1.67
Earnings date21 Apr 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est19.00
  • Company News for Jun 11, 2021

    Company News for Jun 11, 2021

    Companies in the news are: SIG, XIN, VRNA, PFE

  • Globe Newswire

    Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China

    $40 million upfront including $25 million cash and $15 million in equity in Nuance Biotech (parent company) Up to $179 million in potential clinical, regulatory, and commercial milestone payments plus tiered double-digit royalties Nuance Pharma is responsible for all costs related to development and commercialization of ensifentrine in China LONDON and RALEIGH, N.C. and SHANGHAI, China, June 10, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”) and Nuance Pharma Limited

  • Globe Newswire

    Verona Pharma to Present at Jefferies Virtual Healthcare Conference

    LONDON and RALEIGH, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 9:00 AM ET. A webcast of the event will be available for 90 days on the Events and Presentations link on the Investors page of the Company’s website, Verona Pharma plcUS Tel: +1-833-417-0262UK Tel: +44 (0)203 283 4200Victoria Stewart, Director of Argot Partners(US Investor Enquiries)Tel: +1-212-600-1902verona@argotpartners.comKimberly Minarovich / Michael Barron Optimum Strategic Communications(International Media and European Investor Enquiries)Tel: +44 (0)203 950 9144verona@optimumcomms.comMary Clark / Eva Haas / Shabnam Bashir About Verona Pharma Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit Forward-Looking Statements This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our expectations expressed or implied by the forward-looking statements. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.